HEMATOLOGY

The overall response rate was improved with itacitinib plus corticosteroids compared with placebo plus corticosteroids in patients with treatment-naïve acute graft-versus-host disease in the phase III GRAVITAS-301 trial. However, the difference in ORR for the treatment arm compared with the placebo arm was not statistically significant, missing the trial’s primary end point.

In an interview with&nbsp;<em>Targeted Oncology</em>, Constantine S. Tam, MD, discussed the findings of&nbsp;the phase III CAPTIVATE study.&nbsp;

In an interview with&nbsp;Targeted Oncology, Courtney D. DiNardo, MD, discussed the interim analysis results from the ongoing phase II trial evaluating the combination of enasidenib plus azacitidine in newly diagnosed patients with acute myeloid leukemia.

Lori Leslie, MD, discusses toxicities and outcomes observed in patients with chronic lymphocytic leukemia treated with acalabrutinib in real-word clinics.

CLR 131, a small-molecule, targeted Phospholipid Drug Conjugate, has been granted Orphan Drug Designation by the FDA for the treatment of patients with lymphoplasmacytic lymphoma, according to a press release from Cellectar BioSciences, Inc, developer of the drug.<br /> &nbsp;

In a preliminary clinical trial, ARQ 531, an&nbsp;investigational Bruton tyrosine kinase inhibitor, showed safety and clinical activity across a variety of B-cell malignancies.

With the absence of a standard of care for chronic neutrophilic leukemia and atypical chronic myeloid leukemia, 2 rare&nbsp;BCR-ABL1-negative myeloid neoplasms, ruxolitinib may be a viable treatment option after a phase II study showed potential for response in this patient population.

Results from a phase I/Ib trial showed revealed that preliminary activity was seen with IMGN632, an investigational anti-CD123 antibody-drug conjugate, given to patients with relapsed/refractory acute myelogenous leukemia or blastic plasmacytoid dendritic cell neoplasm, according to data presented at the 2019 ASH Annual Meeting.

Rapidly Progressing Acute Myeloid Leukemia